Opendata, web and dolomites


Multi-omics molecular treatment targets for Prostate Cancer

Total Cost €


EC-Contrib. €






Project "PCaProTreat" data sheet

The following table provides information about the project.


Organization address
postcode: 30659

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 171˙460 €
 EC max contribution 171˙460 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-SE
 Starting year 2018
 Duration (year-month-day) from 2018-04-01   to  2020-03-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MOSAIQUES DIAGNOSTICS GMBH DE (HANNOVER) coordinator 171˙460.00


 Project objective

The PCaProTreat Project targets on improving the Prostate Cancer (PCa) management and focuses on the identification of novel therapeutic targets for patients with an advanced disease stage. It has been demonstrated that the current medical practice has led to frequent over-treatment of patients exhibiting slow growing PCa (unlikely to progress in the absence of treatment), while for metastatic castration resistant patients that immediate treatment is required, no effective strategies are available. Therefore, new therapeutic options are required for advanced PCa. To address this clinical demand, PCaProTreat is focused on the comprehensive characterisation of the molecular background of PCa progression, based on which molecularly-driven therapeutic targets can be defined. Towards that end, PCaProTreat includes: a) multi-layer analysis (different types of specimens: tissue, urine, seminal plasma) and multi-omics profiling (proteomics, peptidomics, transcriptomics), supplemented with literature-mined data, b) establishment of the PCa knowledge database, c) data integration into Systems Biology workflow to identify key-regulatory elements responsible for disease progression (best suited drug targets) and d) validation of the selected targets using immunohistochemistry. This multi-dimensional approach represents a substantial advancement over the standards currently applied in drug discovery process, allowing to overcome the challenges associated with tumour heterogeneity and thus reveal optimal drug targets. In parallel to the research activities, a multi-disciplinary and multi-sectorial training program will be implemented to increase the competitiveness of the ER within the research community, to become a recognised researcher. Activities will be carried out in the industrial sector, with Mosaiques Diagnostics a leader in clinical proteomics and Systems Medicine, being a Host institution.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PCAPROTREAT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PCAPROTREAT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

POMOC (2019)

Charles IV and the power of marvellous objects

Read More  

EPIC (2019)

Evolution of Planktonic Gastropod Calcification

Read More  

NeuroSens (2019)

Neuromodulation of Sensory Processing

Read More